The future of drug discovery runs on DaltonTx. Our AI-enabled platforms give pharma, biotech, and CROs the infrastructure modern R&D canât move forward â¨without â transforming the economics, timelines, and outcomes of discovery.
Location: United Kingdom
Investors 1
| Date | Name | Website |
| 04.05.2026 | IQ Capital... | iqcapital.... |
Mentions in press and media 4
| Date | Title | Description |
| 23.03.2026 | SLAS announces the cohort for Innovation AveNEW at SLAS Europe 2026 | Vienna, Austria, 23 March 2026: SLAS, the Society of Laboratory Automation and Screening, has introduced the 12 companies selected for the Innovation AveNEW program at SLAS Europe 2026 Conference and Exhibition, taking place 19-21 May in Vi... |
| 23.09.2025 | DaltonTx lands £4M to advance the intelligence backbone of drug discovery | UK-based technology company DaltonTx has exited stealth and completed a £4 million seed financing round. Backed by Redalpine, IQ Capital Partners, and Seedcamp, with additional support from Oxford University Innovation, DaltonTx will use th... |
| 23.09.2025 | DaltonTx Raises £4M in Seed Financing | DaltonTx, a London, UK-based provider of a disease- and technology-agnostic adaptive platform, raised £4M in Seed funding. Backers included redalpine, IQ Capital Partners, and Seedcamp, and support from Oxford University Innovation. The com... |
| - | DaltonTx | “The future of drug discovery runs on DaltonTx. Our AI-enabled platforms give pharma, biotech, and CROs the infrastructure modern R&D can’t move forward without — transforming the economics, timelines, and outcomes of discovery.”... |